Literature DB >> 15944944

Immunological and molecular aspects of liver fibrosis in chronic hepatitis C virus infection.

G Giannelli1, S Antonaci.   

Abstract

Chronic C hepatitis represents a major health problem worldwide, mainly because progression of the tissue damage leads to the development of cirrhosis and hepatocellular carcinoma. In this review we discuss the molecular mechanisms underlying the development of liver fibrosis. In particular we consider some immunologic aspects that regulate the interaction between HCV and the host immune defense. Reflections are made about the roles played by the host capacity to respond to the viral infection during therapy and the consequences of the deposition of extracellular matrix (ECM) proteins leading to the development of fibrosis. The involvement of inflammatory cytokines in regulating the proteolytic remodeling of the liver and the ECM turn-over is essential for the activation of hepatic stellate cells (HSCs), that have an important role in the progression of liver fibrosis. Finally, we analyze one of the aspects involved in the activation of the HSCs, namely the proteolytic remodeling of the surrounding environment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15944944     DOI: 10.14670/HH-20.939

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  8 in total

1.  Effects of extract from Ginkgo biloba on carbon tetrachloride-induced liver injury in rats.

Authors:  Shui-Xiang He; Jin-Yan Luo; Yue-Peng Wang; Yan-Li Wang; Han Fu; Jun-Li Xu; Gang Zhao; En-Qi Liu
Journal:  World J Gastroenterol       Date:  2006-06-28       Impact factor: 5.742

2.  Immune response to extracellular matrix collagen in chronic hepatitis C-induced liver fibrosis.

Authors:  Brian B Borg; Anil Seetharam; Vijay Subramanian; Haseeb Ilias Basha; Mauricio Lisker-Melman; Kevin Korenblat; Christopher D Anderson; Surendra Shenoy; William C Chapman; Jeffrey S Crippin; Thalachallour Mohanakumar
Journal:  Liver Transpl       Date:  2011-07       Impact factor: 5.799

3.  Protective effect of morin on dimethylnitrosamine-induced hepatic fibrosis in rats.

Authors:  Hee-Seung Lee; Kyung Hee Jung; In-Suh Park; Sung Won Kwon; Don-Haeng Lee; Soon-Sun Hong
Journal:  Dig Dis Sci       Date:  2008-07-17       Impact factor: 3.199

4.  Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma.

Authors:  Jen-Eing Jeng; Jung-Fa Tsai; Lee-Yea Chuang; Mei-Shang Ho; Zu-Yau Lin; Min-Yuh Hsieh; Shin-Chern Chen; Wan-Lung Chuang; Liang-Yen Wang; Ming-Lung Yu; Chia-Yen Dai; Jan-Gowth Chang
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

Review 5.  Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver.

Authors:  Scott L Friedman
Journal:  Physiol Rev       Date:  2008-01       Impact factor: 37.312

6.  Hepatic stellate cells - from past till present: morphology, human markers, human cell lines, behavior in normal and liver pathology.

Authors:  Rada Teodora Sufleţel; Carmen Stanca Melincovici; Bogdan Alexandru Gheban; Zaharie Toader; Carmen Mihaela Mihu
Journal:  Rom J Morphol Embryol       Date:  2020 Jul-Sep       Impact factor: 1.033

7.  Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis.

Authors:  Alena Laschtowitz; Kalliopi Zachou; Vasiliki Lygoura; Simon Pape; Finn Derben; Elmar Jaeckel; Sergio Oller-Moreno; Sören Weidemann; Till Krech; Felix Piecha; Gerhard Schön; Anna-Maria Liebhoff; Munira Al Tarrah; Michael Heneghan; Joost P H Drenth; George Dalekos; Richard Taubert; Ansgar Wilhelm Lohse; Christoph Schramm
Journal:  JHEP Rep       Date:  2021-06-12

Review 8.  The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies.

Authors:  Jun Xu; Xiao Liu; Yukinori Koyama; Ping Wang; Tian Lan; In-Gyu Kim; In H Kim; Hsiao-Yen Ma; Tatiana Kisseleva
Journal:  Front Pharmacol       Date:  2014-07-22       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.